Labcorp Partners with Roche to Integrate Digital Pathology Technology

The move comes amid projections of a shortage of nearly 5,700 pathologists in the U.S. by 2030, coinciding with rising demand for diagnostic services due to an aging population and increased incidence of cancer and other diseases.

Labcorp has announced a collaboration with Roche to implement the company’s FDA-cleared VENTANA® DP 600 and DP 200 slide scanners, aiming to expand digital pathology capabilities across its anatomic pathology services.

"Integrating digital slide scanning into our pathology workflow will help improve accuracy, streamline operations, and enable future AI-driven insights," said Marcia Eisenberg, Ph.D., Labcorp’s chief scientific officer. She emphasized the initiative as part of Labcorp’s ongoing effort to advance diagnostic capabilities.

The move comes amid projections of a shortage of nearly 5,700 pathologists in the U.S. by 2030, coinciding with rising demand for diagnostic services due to an aging population and increased incidence of cancer and other diseases.

The digital pathology workflow converts traditional glass slides into high-resolution digital images that can be accessed and analyzed from conventional PC workstations. This eliminates the need for physical slides, allowing pathologists to review samples and collaborate across multiple locations. Key advantages include rapid sharing for specialist consultations, streamlined workflows, reduced costs, and minimized risks of slide damage or loss. Additionally, the digital infrastructure provides a foundation for AI integration, which could enhance consistency, accuracy, and efficiency in pathology analysis.

"We look forward to expanding our collaboration with Labcorp to advance the digital transformation of their pathology labs," said Michael Rivers, life cycle leader for digital pathology at Roche Tissue Diagnostics. "This collaboration, which combines Labcorp's strength in diagnostic services with Roche's expertise in digital pathology solutions, holds the potential to create new opportunities for highly efficient, timely, and effective patient care."

Labcorp’s investment builds on its existing relationship with Roche and aligns with the company’s broader strategy to expand digital capabilities in Diagnostics and Biopharma Laboratory Services. Globally, Labcorp teams are already leveraging digital pathology technology to support clinical trials, enabling more efficient data sharing, centralized review, and faster decision-making.

Stay tuned for more such updates on Digital Health News